Cargando…
The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
5-Fluorouracil (5-FU) is the backbone of the chemotherapy regimens approved for treatment of many malignancies, especially colorectal cancer (CRC). The incidence of cardiotoxicity associated with 5-FU ranges between 1.5% to 18% and is most commonly manifested as anginal symptoms. Cardiomyopathy is v...
Autores principales: | Saif, Muhammad W, Smith, Melissa, Maloney, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065345/ https://www.ncbi.nlm.nih.gov/pubmed/27752409 http://dx.doi.org/10.7759/cureus.783 |
Ejemplares similares
-
Alternative chemoradiotherapy in anal carcinoma patients with
mutations in thymidylate synthase and dihydropyrimidine dehydrogenase
genes
por: Saif, MW, et al.
Publicado: (2021) -
P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting
por: Gokare, Prashanth, et al.
Publicado: (2017) -
Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism
por: Wang, Bo, et al.
Publicado: (2016) -
Study of Thymidylate Synthase (TS) and Dihydropyrimidine Dehydrogenase (DPD) Expressions on 5-Fluorouracil in Oral Squamous Cell Carcinoma
por: Akhter, Khaleda, et al.
Publicado: (2019) -
Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression
por: Jensen, Søren A, et al.
Publicado: (2009)